Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.11 Bn | 214.41 Mn | -79.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.54% |
| Mar 31, 2026 | 56.05% |
| Dec 31, 2025 | -58.89% |
| Sep 30, 2025 | 50.54% |
| Jun 30, 2025 | 63.63% |
| Dec 31, 2024 | -33.98% |
| Sep 30, 2024 | 7.15% |
| Jun 30, 2024 | -31.79% |
| Mar 31, 2024 | 33.40% |
| Dec 31, 2023 | -131.54% |
| Sep 30, 2023 | 79.03% |
| Jun 30, 2023 | 87.36% |
| Mar 31, 2023 | 11.32% |
| Dec 31, 2022 | 87.34% |
| Sep 30, 2022 | 28.23% |
| Jun 30, 2022 | 41.02% |
| Mar 31, 2022 | 63.44% |
| Dec 31, 2021 | 120.04% |
| Sep 30, 2021 | 107.25% |
| Jun 30, 2021 | 63.50% |